神经分泌生物科学(NBIX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NBIX 神经分泌生物科学

交易中 10-02 11:08:19 EDT

143.89

+3.18

+2.26%

最高144.56	最低140.36	成交量45.95万
今开141.41	昨收140.71	日振幅2.98%
总市值146.77亿	流通市值143.88亿	总股本1.02亿
成交额6,576万	换手率0.46%	流通股本1亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NBIX","market":"US","secType":"STK","nameCN":"神经分泌生物科学","latestPrice":143.89,"timestamp":1790953698241,"preClose":140.71,"halted":0,"volume":459497,"delay":0,"changeRate":0.022599673086489788,"floatShares":99995570,"shares":102000000,"eps":6.823004,"marketStatus":"交易中","change":3.18,"latestTime":"10-02 11:08:19 EDT","open":141.41,"high":144.56,"low":140.36,"amount":65760936.12985,"amplitude":0.029849,"askPrice":143.89,"askSize":135,"bidPrice":143.64,"bidSize":1,"shortable":3,"etf":0,"ttmEps":6.823004,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1790971200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":832824000000,"exchange":"NASDAQ","adjPreClose":140.71,"preHourTrading":{"tag":"盘前","latestPrice":141.41,"preClose":140.71,"latestTime":"09:29 EDT","volume":54708,"amount":7698041.459520001,"timestamp":1790947799999,"change":0.7,"changeRate":0.004975,"amplitude":0.012011},"postHourTrading":{"tag":"盘后","latestPrice":140.71,"preClose":140.71,"latestTime":"19:32 EDT","volume":94607,"amount":13312238.521,"timestamp":1790897558965,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.13124,"impliedVol":0.3792,"impliedVolPercentile":0.5857},"requestUrl":"/m/hq/s/NBIX/tweets","defaultTab":"tweets","newsList":[{"id":"1160477984","title":"Nxera制药株式会社：里程碑付款预计将在2026财年第三季度全额确认为收入","url":"https://stock-news.laohu8.com/highlight/detail?id=1160477984","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160477984?lang=zh_cn&edition=full","pubTime":"2026-08-26 15:33","pubTimestamp":1787729593,"startTime":"0","endTime":"0","summary":"Nxera制药株式会社今日宣布，其里程碑付款预计将在2026财年第三季度被全额确认为收入。这一预期反映了公司在药物研发管线推进过程中所取得的重要进展。分析人士认为，这一收入确认时间节点的明确，为市场提供了更清晰的财务指引，有助于投资者更准确地评估公司在2026财年的业绩表现。Nxera制药株式会社将继续专注于其核心治疗领域的研发工作，并致力于通过创新疗法为患者创造价值，同时为股东带来可持续的长期回报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0889565916.HKD","LU2324357040.USD","NBIX","LU2065171402.SGD","LU0154245673.USD","LU2065170008.USD","BK4139","LU2065171311.SGD","LU0823416689.USD","LU2065169927.USD","LU0320765992.SGD","LU0154245756.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166771716","title":"Nxera Pharma合作伙伴Neurocrine Biosciences获FDA批准，开展NBI-1117567治疗阿尔茨海默病认知障碍的二期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1166771716","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166771716?lang=zh_cn&edition=full","pubTime":"2026-08-26 15:32","pubTimestamp":1787729531,"startTime":"0","endTime":"0","summary":"Nxera Pharma株式会社宣布，其合作伙伴Neurocrine Biosciences已获得美国食品药品监督管理局的IND受理，批准其开展NBI-1117567用于治疗阿尔茨海默病相关认知障碍的二期临床研究。NBI-1117567由Neurocrine Biosciences开发，此次获得FDA的IND受理，意味着该药物有望进入人体临床试验阶段，以评估其在改善阿尔茨海默病患者认知功能方面的安全性和有效性。Nxera Pharma与Neurocrine Biosciences的合作关系在此项目中得以深化，双方共同推进这一潜在创新疗法的开发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065169927.USD","BK4139","LU0823416689.USD","LU0154245756.USD","LU2065171402.SGD","LU0154245673.USD","LU0109394709.USD","LU0889565916.HKD","NBIX","LU2324357040.USD","LU2065170008.USD","LU2065171311.SGD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658911935","title":"板块普涨之际 十只量化评分强劲的大盘医疗保健股","url":"https://stock-news.laohu8.com/highlight/detail?id=2658911935","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658911935?lang=zh_cn&edition=full","pubTime":"2026-08-11 23:27","pubTimestamp":1786462073,"startTime":"0","endTime":"0","summary":"经历 2022-2023年板块低迷后，医疗保健板块在2026年重新积聚上涨动能。Centene Corporation以4.97分接近满分的量化评分位居榜单首位；Corcept Therapeutics、Bright Spring Health Services紧随其后，评分分别为4.93、4.91；Halozyme Therapeutics、Humana跻身前五，均获强烈“买入”评级。即便板块整体处在历史高位，个股之间量化评分分化依旧显著。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/YzM0ZmE0OGYyYmI1ZTk0YjVmZmU4ZTU4MTIzMDA2MDU4MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303689","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU0390134368.USD","SG9999014880.SGD","IE00B19Z8W00.USD","IE00B7KXQ091.USD","LU0143551892.USD","LU0114720955.EUR","LU2211815571.USD","LU0154245756.USD","LU0211327993.USD","LU2065170008.USD","LU2491049909.HKD","BK4196","LU1720051017.SGD","IE00BJJMRY28.SGD","IE00BJJMRX11.SGD","LU2242649171.HKD","LU0787776722.HKD","LU0528227936.USD","LU0557290698.USD","LU0128525689.USD","SG9999014013.SGD","IE0004445015.USD","LU0320765059.SGD","LU2125154935.USD","LU2361045086.USD","LU0053666078.USD","LU0158827781.USD","IE00BZ1G4Q59.USD","HRTS","LU0048584097.USD","SG9999017495.SGD","LU2244417387.USD","IE00B19Z3581.USD","LU1201861249.SGD","SG9999018857.SGD","BK4528","LU1988902786.USD","LU0708994859.HKD","LU0208291251.USD","LU0128525929.USD","LU0170899867.USD","LU1201861165.SGD","LU0094547139.USD","LU0149725797.USD","SOLV","CNCG","LU0070302665.USD","IE00BJJMRZ35.SGD","LU0648000940.SGD","BK4613","IE00BFSS7M15.SGD","RXL","LU0079474960.USD","IE00BFSS8Q28.SGD","FBT","IE00B19Z9505.USD","IE00BWXC8680.SGD","IE00B4R5TH58.HKD","LU0708995401.HKD","LU1267930573.SGD","IE00BJT1NW94.SGD","LU0052756011.USD","LU1551013425.SGD","LU2065171402.SGD","IE0002270589.USD","BK4504","LU2361044949.HKD","LU0320765489.SGD","LU1699723380.USD","LU2089284900.SGD","SG9999018865.SGD","BK4533","LU0162691827.USD","LU1854103824.USD","LU0203345920.USD","LU1989764664.SGD","FFOX","LU1674673428.USD","LU0861579265.USD","PSCH","LU0109391861.USD","IXJ","LU1064131342.USD","LU2491050154.USD","IE00B19Z9P08.USD","LU0072461881.USD","IHF","BTSG","LU1506573853.SGD","LU0345770308.USD","LU1093756325.SGD","LU0256863811.USD","LU0251132253.USD","LU0058720904.USD","SG9999001176.USD","LU0187121727.USD","SGXZ99366536.SGD","LU0203347892.USD","LU0109394709.USD","LU2125154778.USD","LU0859254822.USD","LU2023251221.USD","LU1035773651.USD","LU1670627923.USD","HUM","BK4154","LU2028103732.USD","SG9999001176.SGD","FHLC","TRUH","LU2999663052.SGD","LU0158827948.USD","LU1074936037.SGD","LU2362541273.HKD","LU2468319806.SGD","LU0130517989.USD","LU0477156953.USD","IE00B1XK9C88.USD","LU1732800096.USD","SG9999014906.USD","LU2461242641.AUD","LU0316494557.USD","LU1791710582.SGD","IE00BZ9MQY76.HKD","LU0456855351.SGD","LU1066051225.USD","IE00BFXG1179.USD","LU1989771016.USD","IE00B775H168.HKD","SG9999014914.USD","IE00B894F039.SGD","LU0130518102.USD","LU1066051811.HKD","LU1718418525.SGD","LU0154245673.USD","LU0011850046.USD","FXH","LU1674673691.USD","IE00BKVL7J92.USD","LU0965508806.USD","BK4581","LU2087625088.SGD","JDOC","LU1084165304.USD","BK4007","LU2324357040.USD","LU0661504455.SGD","LU1267930227.SGD","LU2357305700.SGD","LU0266013472.USD","LU2089984988.USD","LU2462591277.SGD","BK4139","LU1989764748.USD","BK4198","BK4534","IE00BFTCPJ56.SGD","LU1720051108.HKD","IE000M9KFDE8.USD","SGXZ51526630.SGD","LU0889565916.HKD","IE00B19Z3B42.SGD","LU0320765992.SGD","IE00B3T34201.USD","LU1814569148.SGD","LU0122379950.USD","LU0310799852.SGD","LU0211328371.USD","LU0353189763.USD","LU0648001328.SGD","LU0882574055.USD","LU1069347547.HKD","SG9999014021.USD","LU0820561818.USD","LU1983299246.USD","LU0342679015.USD","LU0965509283.SGD","LU0672654240.SGD","LU1267930730.SGD","SGXZ31699556.SGD","LU1732799900.SGD","PTH","SG9999002224.SGD","LU0345770993.USD","LU0353189680.USD","LU2065171311.SGD","LU0097036916.USD","SG9999002232.USD","LU0198837287.USD","BK4585","LU0432979614.USD","LU0689472784.USD","LU0211326755.USD","LU2279689827.SGD","BK4532","LU2111349929.HKD","LU0238689110.USD","LU2065169927.USD","LU1153585028.USD","LU1323610961.USD","SGXZ81514606.USD","LU0820561909.HKD","LU1983260115.SGD","BK4559","LU1061106388.HKD","LU0980610538.SGD","LU0965509101.SGD","LU0943347566.SGD","IE00BN29S564.USD","LU1778281490.HKD","LU2271345857.HKD","LU2361044865.SGD","LU0130102774.USD","IE0002141913.USD","LU0795875086.SGD","IE0009355771.USD","LU1037948541.HKD","LU0823416689.USD","LU1057294990.SGD","LU1037948897.HKD","LU0477156797.USD","GDOC","XLV","LU1093756168.USD","SG9999014005.SGD","LU1003077747.HKD","LU2347655156.SGD","LU1291159041.SGD","CNC","LU0211331839.USD","LU1934455277.USD","UNHG","LU0965509010.AUD","LU1854104046.USD","LU1267930490.SGD","LU2264538146.SGD","DVA","LU0053671581.USD","LU0354030438.USD","MHIP","LU1791710400.SGD","LU0795875169.SGD","LU0683600562.USD","LU0566484027.USD","LU0234572021.USD","IYH","LU2112291526.USD","LU2089283258.USD","LU2491050071.SGD","IE00B1BXHZ80.USD","BK4588","LU0949170772.SGD","IE00B19Z8X17.USD","LU0738911758.USD","LU1914381329.SGD","LU1670628061.USD","LU1934455194.USD","LU2552382058.USD","LU1261432733.SGD","LU0310800965.SGD","LU1066051498.USD","LU0348723411.USD","LU0077335932.USD","IE0034235188.USD","LU0289739699.SGD","LU1559883803.SGD","NBIX","LU1023059063.AUD","EKG","LU2362541513.USD","LU2954938101.SGD","LU2552382215.SGD","LU0976567544.SGD","TMED","IE00B2B36J28.USD","LU0496365809.HKD","IE00B19Z9Z06.USD","SG9999014898.SGD","BK4566","CORT","LU0029864427.USD","LU0417517546.SGD","VHT","LGHT","UNHW","IE00BSNM7G36.USD","LU2362540622.SGD","LU1066053197.SGD","LU0545039389.USD","SGXZ57979304.SGD","LU2552382132.HKD","IE00B4JS1V06.HKD","LU1496350502.SGD","IE0005OL40V9.USD","LU0553294199.USD","LU0912757837.SGD","LU2133065610.SGD","IE00B7SZLL34.SGD","LU0107464264.USD","LU1548497426.USD","IE0004445239.USD","LU0354030511.USD","LU2360032135.SGD","LU0310800379.SGD","SG9999013999.USD","LU1119994496.HKD","LU2236285917.USD","HALO","LU0820562030.AUD","UNH","LU2357627491.SGD","LU0130103400.USD","VEEV","BK4167","LU1934455863.HKD","LU1551013342.USD","LU0211326839.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121785972","title":"神经分泌生物科学启动Nbip-'1968（GLP-1/GIP/胰高血糖素三重激动剂）一期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1121785972","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121785972?lang=zh_cn&edition=full","pubTime":"2026-08-07 20:31","pubTimestamp":1786105871,"startTime":"0","endTime":"0","summary":"神经分泌生物科学公司宣布，已正式启动一项针对Nbip-'1968的1期临床研究。该药物是一种GLP-1/GIP/胰高血糖素受体三重激动剂，旨在探索其在代谢疾病领域的潜在治疗价值。这一研究标志着该候选药物从实验室走向人体试验的关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","LU0889565916.HKD","LU0154245673.USD","LU0154245756.USD","LU0823416689.USD","LU2065171311.SGD","LU2065171402.SGD","LU2324357040.USD","LU0320765992.SGD","LU0109394709.USD","BK4139","LU2065169927.USD","NBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176695291","title":"异动解读｜神经分泌生物科学盘中下跌9.92%，Q2业绩大超预期后股价承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1176695291","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176695291?lang=zh_cn&edition=full","pubTime":"2026-08-01 00:13","pubTimestamp":1785514417,"startTime":"0","endTime":"0","summary":"8月1日，神经分泌生物科学盘中下跌9.92%，报167.10美元/股，成交额3.76亿美元。消息面上，公司于7月30日盘后公布Q2财报，调整后每股收益2.85美元，同比增长72.73%，远超市场一致预期的1.34美元，超预期幅度达112.69%；营收9.59亿美元，同比增长39.4%，超出预期的8.83亿美元。公司同时将核心产品Ingrezza全年净销售额指引上调至28.25亿至28.75亿美元。尽管业绩全面超预期且上调指引，股价仍出现大幅回调。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195058603","title":"神经分泌生物科学Q2调整后每股收益2.85美元，远超市场预期的1.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1195058603","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195058603?lang=zh_cn&edition=full","pubTime":"2026-07-31 04:13","pubTimestamp":1785442436,"startTime":"0","endTime":"0","summary":"神经分泌生物科学公司第二季度业绩表现强劲。调整后每股收益达2.85美元，而市场普遍预期仅为1.34美元，这一结果显著超出分析师的预估。\n在第二季度，该公司公布的每股收益为1.39美元。（完）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154245756.USD","BK4139","LU0823416689.USD","LU2324357040.USD","LU2065169927.USD","LU0154245673.USD","LU2065170008.USD","LU0109394709.USD","LU0889565916.HKD","LU2065171311.SGD","LU2065171402.SGD","LU0320765992.SGD","NBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142591184","title":"神经分泌生物科学上调Ingrezza(Valbenazine) 2026年净销售额指引至28.25亿至28.75亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1142591184","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142591184?lang=zh_cn&edition=full","pubTime":"2026-07-31 04:04","pubTimestamp":1785441857,"startTime":"0","endTime":"0","summary":"神经分泌生物科学公司（Neurocrine Biosciences, Inc）近日宣布，将其核心产品Ingrezza（Valbenazine）2026年的净销售额预期上调。新的预测区间设定在28.25亿美元至28.75亿美元之间。这一调整反映了公司对市场前景的乐观预期，以及该药物在治疗领域持续增长的动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154245756.USD","LU0889565916.HKD","LU0823416689.USD","LU2065170008.USD","LU0320765992.SGD","LU2065169927.USD","LU2324357040.USD","LU2065171311.SGD","NBIX","LU0109394709.USD","LU0154245673.USD","LU2065171402.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105854416","title":"财报前瞻｜神经分泌生物科学本季度营收预计增34.84%，机构观点看多占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1105854416","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105854416?lang=zh_cn&edition=full","pubTime":"2026-07-23 12:07","pubTimestamp":1784779678,"startTime":"0","endTime":"0","summary":"神经分泌生物科学将于2026年07月30日发布最新季度财报，市场预期营收和盈利延续高增势头，核心产品动能与新产品商业化将成为关注焦点。市场一致预期本季度神经分泌生物科学总营收为8.80亿美元，同比增长34.84%；调整后每股收益为1.31美元，同比增长35.19%。结合本季度一致预期，营收预计8.80亿美元、同比增长34.84%，若核心产品的新患者启动与持续用药强度维持上季度水平或略有改善，收入端的可视性较好。当前机构观点以看多为主。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜神经分泌生物科学本季度营收预计增34.84%，机构观点看多占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132713140","title":"神经分泌生物科学启动Crinecerfont针对4岁以下经典先天性肾上腺皮质增生症患儿的2期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1132713140","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132713140?lang=zh_cn&edition=full","pubTime":"2026-07-02 04:07","pubTimestamp":1782936442,"startTime":"0","endTime":"0","summary":"神经分泌生物科学公司已启动一项针对四岁以下经典先天性肾上腺皮质增生症（CAH）儿科患者的2期临床研究，以评估其候选药物Crinecerfont的疗效与安全性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","LU0154245756.USD","LU0320765992.SGD","LU2065171311.SGD","LU2324357040.USD","LU2065170008.USD","NBIX","LU0109394709.USD","LU0823416689.USD","LU0889565916.HKD","BK4139","LU2065169927.USD","LU0154245673.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108171843","title":"神经分泌生物科学公布迟发性运动障碍治疗新临床应答数据，强化Ingrezza®（缬苯那嗪）胶囊在广泛患者群体中的疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1108171843","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108171843?lang=zh_cn&edition=full","pubTime":"2026-06-09 04:06","pubTimestamp":1780949176,"startTime":"0","endTime":"0","summary":"神经分泌生物科学公布了关于迟发性运动障碍治疗的最新临床意义应答数据。这些数据进一步证实了Ingrezza®（缬苯那嗪）胶囊在广泛患者群体中展现出的显著疗效。新信息强化了该疗法应对这一挑战性运动障碍的有效性，为更全面的患者管理提供了支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065169927.USD","BK4139","LU0823416689.USD","LU0154245756.USD","LU2065171402.SGD","LU0154245673.USD","LU0109394709.USD","LU0889565916.HKD","NBIX","LU2324357040.USD","LU2065170008.USD","LU2065171311.SGD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105742910","title":"异动解读｜神经分泌生物科学盘中上涨5.85%，机构看好Crenessity商业化前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1105742910","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105742910?lang=zh_cn&edition=full","pubTime":"2026-06-04 00:16","pubTimestamp":1780503392,"startTime":"0","endTime":"0","summary":"消息面上，加拿大皇家银行资本市场近日将该公司目标价从180美元上调至183美元，维持跑赢大盘评级，并发布研报指出Crenessity商业化增长仍有更多上行空间。RBC对35位内分泌科医生的调查显示，受访医生目前平均在约23%的相关患者中使用Crenessity，预计到年底将提升至37%。RBC据此将Crenessity全年销售预期从7.34亿美元上调至7.5亿美元，显著高于市场约6.5亿美元的一致预期，认为即使在更保守的增长假设下该目标仍可实现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191847458","title":"异动解读 | Crenessity®专家建议发表，神经分泌生物科学盘前大涨5.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=1191847458","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191847458?lang=zh_cn&edition=full","pubTime":"2026-05-06 21:56","pubTimestamp":1778075761,"startTime":"0","endTime":"0","summary":"神经分泌生物科学（NBIX）今日盘前股价大涨5.86%，引起了市场的广泛关注。消息面上，神经分泌生物科学公司宣布，关于启动Crenessity®（Crinecerfont）治疗经典先天性肾上腺皮质增生症后如何减少糖皮质激素用量的专家建议已正式发表。该方案为临床医生提供了重要指导，旨在优化治疗策略并改善患者预后，这被视为公司在该药物研发和商业化进程中的积极进展，增强了投资者信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100486194","title":"神经分泌生物科学公布专家建议：启动Crenessity®治疗经典先天性肾上腺皮质增生症后糖皮质激素减量方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1100486194","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100486194?lang=zh_cn&edition=full","pubTime":"2026-05-06 20:31","pubTimestamp":1778070686,"startTime":"0","endTime":"0","summary":"神经分泌生物科学公司宣布，关于启动Crenessity®（Crinecerfont）治疗经典先天性肾上腺皮质增生症后如何减少糖皮质激素用量的专家建议已正式发表。该方案为临床医生提供了重要指导，旨在优化治疗策略并改善患者预后。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065169927.USD","LU2324357040.USD","LU0889565916.HKD","LU0320765992.SGD","LU0154245756.USD","LU2065171311.SGD","BK4139","LU0154245673.USD","LU2065171402.SGD","LU2065170008.USD","NBIX","LU0823416689.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131770926","title":"神经分泌生物科学公布新调查结果：迟发性运动障碍对就业构成显著负担","url":"https://stock-news.laohu8.com/highlight/detail?id=1131770926","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131770926?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:32","pubTimestamp":1777897948,"startTime":"0","endTime":"0","summary":"神经分泌生物科学公司近日发布了一项新的调查结果，该结果揭示了迟发性运动障碍对患者就业状况产生的显著负面影响。调查显示，这一神经系统疾病不仅严重影响患者的日常生活质量，更对其职业发展和工作能力构成了沉重负担。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4139","LU0320765992.SGD","LU0823416689.USD","LU0109394709.USD","LU0154245756.USD","LU2065171311.SGD","LU2324357040.USD","LU2065171402.SGD","NBIX","LU2065169927.USD","LU2065170008.USD","LU0154245673.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134439642","title":"神经分泌生物科学启动评估NBIP-'2118的1期临床研究，该药物为促肾上腺皮质激素释放因子2型受体激动剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1134439642","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134439642?lang=zh_cn&edition=full","pubTime":"2026-05-04 19:54","pubTimestamp":1777895680,"startTime":"0","endTime":"0","summary":"神经分泌生物科学公司宣布，已正式启动一项1期临床研究，旨在评估其在研药物NBIP-'2118。该药物是一种促肾上腺皮质激素释放因子2型受体激动剂。\n此项1期研究的初步数据预计将于2027年公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","BK4139","LU0109394709.USD","LU0889565916.HKD","LU2065170008.USD","LU0154245756.USD","LU0320765992.SGD","LU2065171311.SGD","LU2065171402.SGD","LU2324357040.USD","NBIX","LU2065169927.USD","LU0154245673.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100622320","title":"神经分泌生物科学启动评估Nbip-'2118的I期临床研究，该药物为促肾上腺皮质激素释放因子2型受体激动剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1100622320","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100622320?lang=zh_cn&edition=full","pubTime":"2026-05-04 19:32","pubTimestamp":1777894337,"startTime":"0","endTime":"0","summary":"生物制药公司神经分泌生物科学宣布，正式启动一项I期临床研究，旨在评估其在研药物Nbip-'2118。该药物是一种促肾上腺皮质激素释放因子2型受体激动剂。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","BK4139","LU0109394709.USD","LU0889565916.HKD","LU2065170008.USD","LU0154245756.USD","LU0320765992.SGD","LU2065171311.SGD","LU2065171402.SGD","LU2324357040.USD","NBIX","LU2065169927.USD","LU0154245673.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181164572","title":"神经分泌生物科学公布Crenessity®（Crinecerfont）两年新数据：证实对经典先天性肾上腺增生症儿科患者具有持久激素控制、减少糖皮质激素暴露及显著临床改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1181164572","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181164572?lang=zh_cn&edition=full","pubTime":"2026-05-02 04:06","pubTimestamp":1777665978,"startTime":"0","endTime":"0","summary":"神经分泌生物科学公司最新公布的两年期临床研究数据显示，其研发的Crenessity®（Crinecerfont）在治疗经典先天性肾上腺增生症的儿科患者方面展现出持续疗效。该数据证实，该疗法能够实现持久的激素水平控制，显著降低患者对糖皮质激素的暴露剂量，并为患儿带来具有临床意义的症状改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","LU0154245756.USD","NBIX","BK4139","LU0889565916.HKD","LU0154245673.USD","LU0109394709.USD","LU0320765992.SGD","LU2065169927.USD","LU2065170008.USD","LU0823416689.USD","LU2065171402.SGD","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625693674","title":"Neurocrine斥资29亿美元收购Soleno，进军代谢疾病领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2625693674","media":"智通财经网","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2625693674?lang=zh_cn&edition=full","pubTime":"2026-04-07 06:05","pubTimestamp":1775513144,"startTime":"0","endTime":"0","summary":"Neurocrine Biosciences周一表示，将以现金29亿美元收购罕见病药企Soleno Therapeutics，标志着这家专注神经科学领域的制药公司向代谢疾病领域扩张。","market":"sg","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425299.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Neurocrine斥资29亿美元收购Soleno，进军代谢疾病领域","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0889565916.HKD","LU0823416689.USD","LU0320765992.SGD","SLNO","LU2065170008.USD","LU0154245673.USD","NBIX","LU2324357040.USD","BK4139","LU0154245756.USD","LU2065171402.SGD","LU2065169927.USD","LU2065171311.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146320564","title":"特定条件下交易终止时 Soleno 将向 Neurocrine 支付9.53亿美元解约金","url":"https://stock-news.laohu8.com/highlight/detail?id=1146320564","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146320564?lang=zh_cn&edition=full","pubTime":"2026-04-06 19:39","pubTimestamp":1775475553,"startTime":"0","endTime":"0","summary":"根据最新披露的协议条款，若此次并购交易因特定情形被迫终止，Soleno Therapeutics（SLNO）需向Neurocrine Biosciences（NBIX）支付高达9.53亿美元的解约费用。这一条款为交易设置了明确的风险对冲机制。\n该金额的设定反映出双方对交易价值的共同认知，同时也为可能出现的意外情况提供了契约保障。分析师指出，此类终止费条款在生物医药行业并购中较为常见，既能保护收购方利益，又体现了卖方的交易诚意。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU2324357040.USD","LU2065171311.SGD","LU2065169927.USD","SLNO","LU0154245673.USD","NBIX","LU0889565916.HKD","LU0109394709.USD","LU2065171402.SGD","BK4139","LU0154245756.USD","LU2065170008.USD","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197470067","title":"Soleno Therapeutics股价盘前飙升30%，传神经分泌生物科学接近达成25亿美元收购协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1197470067","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197470067?lang=zh_cn&edition=full","pubTime":"2026-04-06 16:35","pubTimestamp":1775464514,"startTime":"0","endTime":"0","summary":"有报道称神经分泌生物科学（Neurocrine Biosciences）即将以约25亿美元的价格收购Soleno Therapeutics，这一消息推动后者股价在盘前交易中大幅上涨30%。市场对这笔潜在交易反应热烈，反映出投资者对两家公司战略整合前景的积极预期。\n此次收购若成功落地，将成为神经科学领域近年来的重要并购案例。神经分泌生物科学通过整合Soleno Therapeutics的研发管线，有望强化其在中枢神经系统治疗领域的布局。盘前交易量的显著增长，也体现出资本市场对行业资源整合的高度关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU2065170008.USD","LU0823416689.USD","LU2065171402.SGD","LU2324357040.USD","LU0154245673.USD","LU2065171311.SGD","BK4139","NBIX","LU0320765992.SGD","SLNO","LU0154245756.USD","LU2065169927.USD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurocrine.com","stockEarnings":[{"period":"1week","weight":0.0127},{"period":"1month","weight":-0.1024},{"period":"3month","weight":-0.1925},{"period":"6month","weight":0.0692},{"period":"1year","weight":0.0271},{"period":"ytd","weight":-0.0079}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":0.0029},{"period":"3month","weight":0.0258},{"period":"6month","weight":0.1649},{"period":"1year","weight":0.1429},{"period":"ytd","weight":0.1204}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Neurocrine Biosciences, Inc.于1992年1月在加利福尼亚州注册成立，并于1996年5月在特拉华州重新注册成立。该公司是一家专注于神经科学的生物制药公司，致力于发现、开发及商业化针对未充分解决的神经、精神、内分泌及免疫系统疾病的治疗方法。其产品组合涵盖美国食品药品监督管理局批准用于治疗迟发性运动障碍、亨廷顿病相关舞蹈病、经典先天性肾上腺皮质增生症、子宫内膜异位症及子宫肌瘤的疗法，并在核心治疗领域拥有从小分子到基因疗法的多元化在研管线。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.064262},{"month":2,"riseRate":0.3,"avgChangeRate":-0.015369},{"month":3,"riseRate":0.4,"avgChangeRate":-0.008794},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.012154},{"month":5,"riseRate":0.6,"avgChangeRate":0.054007},{"month":6,"riseRate":0.548387,"avgChangeRate":0.02095},{"month":7,"riseRate":0.483871,"avgChangeRate":-0.00225},{"month":8,"riseRate":0.516129,"avgChangeRate":0.019578},{"month":9,"riseRate":0.548387,"avgChangeRate":0.023683},{"month":10,"riseRate":0.548387,"avgChangeRate":0.028502},{"month":11,"riseRate":0.6,"avgChangeRate":0.039502},{"month":12,"riseRate":0.633333,"avgChangeRate":0.040009}],"exchange":"NASDAQ","name":"神经分泌生物科学","nameEN":"Neurocrine Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"神经分泌生物科学(NBIX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供神经分泌生物科学(NBIX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"神经分泌生物科学,NBIX,神经分泌生物科学股票,神经分泌生物科学股票老虎,神经分泌生物科学股票老虎国际,神经分泌生物科学行情,神经分泌生物科学股票行情,神经分泌生物科学股价,神经分泌生物科学股市,神经分泌生物科学股票价格,神经分泌生物科学股票交易,神经分泌生物科学股票购买,神经分泌生物科学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"神经分泌生物科学(NBIX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供神经分泌生物科学(NBIX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}